QNTM News & Events

QNTM Stock trading halted, news pending

Quantum BioPharma announced a milestone in its collaborative study with Massachusetts General Hospital: patient enrollment has reached the halfway mark, accompanied by preliminary imaging results. This study is designed to validate a novel positron emission tomography imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis-a critical step toward transforming how disease progression and treatment response are measured.

Quantum BioPharma announced that it has formally submitted an investigational new drug application to the FDA for Lucid-21-302, its new drug candidate for the treatment of multiple sclerosis.

Quantum BioPharma announced that it has entered into a binding letter of intent with Allucent to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis. The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS. Quantum BioPharma expects to initiate the Phase 2 trial in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operational arrangements. Under the terms of the LOI, Allucent will provide comprehensive clinical trial services designed to support efficient execution and data integrity throughout the study.